Tacrolimus-eluting stent inhibits neointimal hyperplasia via calcineurin/NFAT signaling in porcine coronary artery model

Atherosclerosis

Volumn 208, Issue 1, 2010, Pages 97-103

  Hamada, Narisato ^a   Miyata, Masaaki ^a   Eto, Hideyuki ^a   Shirasawa, Takahiro ^a   Akasaki, Yuichi ^a   Nagaki, Aya ^a   Tei, Chuwa ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Calcineurin; Neointimal hyperplasia; NFAT; Smooth muscle cell; Tacrolimus eluting stent

Indexed keywords

CALCINEURIN; INTERLEUKIN 2; SMALL INTERFERING RNA; TACROLIMUS; TRANSCRIPTION FACTOR NFAT;

ANGIOCARDIOGRAPHY; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; BARE METAL STENT; CELL PROLIFERATION; CONTROLLED STUDY; CORONARY ARTERY; DRUG ELUTING STENT; DRUG MECHANISM; FEMALE; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SMOOTH MUSCLE FIBER; SWINE; UPREGULATION; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

ANIMALS; CALCINEURIN; CELLS, CULTURED; CORONARY VESSELS; DRUG-ELUTING STENTS; HYPERPLASIA; IMMUNOSUPPRESSIVE AGENTS; MODELS, ANIMAL; MUSCLE, SMOOTH, VASCULAR; NFATC TRANSCRIPTION FACTORS; RATS; SIGNAL TRANSDUCTION; SWINE; TACROLIMUS; TUNICA INTIMA;

EID: 73449115643     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.07.040     Document Type: Article

References (29)

1. Bennett M.R. In-stent stenosis: pathology and implications for the development of drug eluting stents. Heart 89 2 (2003) 218-224
2. Ezhov M.V., Sumarokov A.B., Raimbekova I.R., Masenko V.P., and Naumov V.G. Interleukin 6 but not interleukin 10 is associated with restenosis after coronary stenting. Atherosclerosis 169 1 (2003) 193-194
3. Liistro F., Stankovic G., Di Mario C., et al. First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome. Circulation 105 16 (2002) 1883-1886
4. Stefanadis C., Toutouzas K., and Stefanadi E. Inhibition of plaque neovascularization and intimal hyperplasia by specific targeting vascular endothelial growth factor with bevacizumab-eluting stent: an experimental study. Atherosclerosis 195 2 (2007) 269-276
5. Deuse T., Erben R.G., Ikeno F., et al. Introducing the first polymer-free leflunomide eluting stent. Atherosclerosis 200 1 (2008) 126-134
6. Morice M.C., Serruys P.W., Sousa J.E., et al. Randomized study with the sirolimus-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346 23 (2002) 1773-1780
7. Stone G.W., Ellis S.G., Cox D.A., et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350 3 (2004) 221-231
8. Moses J.W., Leon M.B., Popma J.J., et al. SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 14 (2003) 1315-1323
9. Silber S. Paclitaxel-eluting stents: are they all equal? An analysis of six randomized controlled trials in de novo lesions of 3,319 patients. J Interv Cardiol 16 6 (2003) 485-490
10. Stone G.W., Moses J.W., Ellis S.G., et al. Safety and efficacy of sirolimus and paclitaxel-eluting coronary stents. N Engl J Med 356 10 (2007) 998-1008
11. Joner M., Finn A.V., Farb A., et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48 1 (2006) 193-202
12. Finn A.V., Nakazawa G., Joner M., et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 27 7 (2007) 1500-1510
13. Tanimoto S., Giessen W.J., Beusekom H.M., et al. MAHOROBA: Tacrolimus eluting coronary stent. Eurointervention 3 (2007) 149-153
14. Thomson A.W., Bonham C.A., and Zeevi A. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit 17 6 (1995) 584-591
15. Wallemacq P.E., and Reding R. FK506 (tacrolimus), a novel immunosuppressant in organ transplantation: clinical, biomedical, and analytical aspects. Clin Chem 9 11 (1993) 2219-2228
16. Matter C.M., Rozenberg I., Jaschko A., et al. Effects of tacrolimus or sirolimus on proliferation of vascular smooth muscle and endothelial cells. J Cardiovasc Pharmacol 48 6 (2006) 286-292
17. Eto H., Biro S., Miyata M., et al. Angiotensin II type 1 receptor participates in extracellular matrix production in the late stage of remodeling after vascular injury. Cardiovasc Res 59 1 (2003) 200-211
18. Schwartz R., Murphy J., Edwards W., Camrud A., Vliestra R., and Holmes D. Restenosis after balloon angioplasty: a practical proliferative model in porcine coronary arteries. Circulation 82 6 (1990) 2190-2200
19. Eto H., Miyata M., Kume N., et al. Expression of lectin-like oxidized LDL receptor-1 in smooth muscle cells after vascular injury. Biochem Biophys Res Commun 341 2 (2006) 591-598
20. Miyata M., Biro S., Kaieda H., et al. Apolipoprotein J/clusterin is induced in vascular smooth muscle cells after vascular injury. Circulation 104 12 (2001) 1407-1412
21. Fukuda D., Enomoto S., Shirakawa I., Nagai R., and Sata M. Fluvastatin accelerates re-endothelialization impaired by local sirolimus treatment. Eur J Pharmacol 612 1-3 (2009) 87-92
22. Liu Z., Zhang C., Dronadula N., Li Q., and Rao G.N. Blockade of nuclear factor of activated T cells activation signaling suppresses balloon injury-induced neointima formation in a rat carotid artery model. J Biol Chem 280 15 (2005) 14700-14708
23. Miyata M., and Smith J.D. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and β-amyloid peptide. Nat Genet 14 1 (1996) 55-61
24. Miyata M., Biro S., Kaieda H., and Tanaka H. Lipoprotein (a) stimulates the proliferation of cultured human arterial smooth muscle cells through two pathways. FEBS Lett 377 3 (1995) 493-496
25. Virmani R., Guagliumi G., Farb A., et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?. Circulation 109 6 (2004) 701-705
26. Lang N.N., and Newby D.E. Emerging thrombotic effects of drug eluting stents. Arterioscler Thromb Vasc Biol 27 2 (2007) 261-262
27. Virmani R., Farb A., and Kolodgie F.D. Histopathologic alterations after endovascular radiation and antiproliferative stents: similarities and differences. Herz 27 1 (2002) 1-6
28. Bartorelli A.L., Trabattoni D., Fabbiocchi F., et al. Synergy of passive coating and targeted drug delivery: the tacrolimus-eluting Janus CarboStent. J Interv Cardiol 16 6 (2003) 499-505
29. Romagnoli E., Leone A.M., Burzotta F., et al. Outcomes of the tacrolimus drug-eluting Janus stent: a prospective two-centre registry in high-risk patients. J Cardiovasc Med 9 6 (2008) 589-594